Literature DB >> 7471739

The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.

D J Back, M Bates, A Bowden, A M Breckenridge, M J Hall, H Jones, M MacIver, M Orme, E Perucca, A Richens, P H Rowe, E Smith.   

Abstract

In a group of 5 women on long-term anticonvulsant and oral contraceptive therapy, the plasma ethynylestradiol (EE) concentration on 50 microgram EE daily was 11.1 +/- 4.5 pg/ml. These values were at the lower end of the range found in normal women in this laboratory taking 30 microgram EE daily (6-190 pg/ml). Four women have been studied prospectively for 3 months, over 1 cycle before and 2 cycles during phenobarbital 30 mg b.i.d. therapy. Significant falls in the plasma EE concentration were seen in two women (from 104.8 +/- 13.4 to 37.7 +/- 2.0 pg/ml and from 125.6 +/- 23.8 to 34.8 +/- 6.7 pg/ml p less than 0.01) and breakthrough bleeding was seen in both women. No changes in plasma concentrations of follicle stimulating hormone, progesterone, norethindrone or norgestrel were seen. There was a significant increase in the sex hormone binding globulin capacity from 100.7 +/- 5.8 to 133.3 +/- 1.2 nmoles/1 (p less than 0.05). These changes are consistent with the known microsomal enzyme inducing effect of phenobarbital.

Entities:  

Keywords:  Contraception; Contraceptive Agents, Estrogen--analysis; Contraceptive Agents, Female--analysis; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--analysis; Contraceptive Methods--side effects; Ethinyl Estradiol--analysis; Family Planning; Follicle Stimulating Hormone; Metrorrhagia; Norethindrone--analysis; Norgestrel--analysis; Oral Contraceptives--side effects; Progesterone; Prospective Studies; Research Methodology; Retrospective Studies; Studies

Mesh:

Substances:

Year:  1980        PMID: 7471739     DOI: 10.1016/0010-7824(80)90102-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  24 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 2.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Anti-epileptic drugs and hormonal treatments.

Authors:  Clare A Johnston; Pamela M Crawford
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

4.  Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes.

Authors:  A P Li; N R Hartman; C Lu; J M Collins; J M Strong
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 5.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

Review 6.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 7.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 8.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 9.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 10.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.